中国临床药学杂志2025，Vol.34Issue(4)：296-300,5.DOI:10.19577/j.1007-4406.2025.04.010
瑞舒伐他汀强化降脂方案对冠心病患者血脂及心率变异性的影响
Effect of rosuvastatin-intensive lipid-lowering therapy on plasma lipids and heart rate variability in patients with coronary heart disease
摘要
Abstract
AIM To investigate the effect of rosuvastatin-intensive lipid-lowering therapy on plasma lipids and heart rate variability in patients with coronary heart disease.METHODS A total of 254 patients with coronary heart disease admitted to the hospital from June 2021 to June 2023 were selected and divided into conventional group and intensive group according to the random number table method,with 127 patients in each group.Patients in the conventional group(n=127)received rosuvastatin 10 mg,po,qd and patients in the intensive group(n=127)received rosuvastatin 20 mg,po,qd.The changes in blood lipid indexes[triglycerides(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],heart rate variability indexes[mean standard deviation of normal R-R intervals(SDANN),standard deviation of normal R-R intervals(SDNN),percentage of adjacent R-R intervals differing by more than 50 ms(pNN50)],and hemorheological parameters(plasma viscosity,whole blood low-shear viscosity,and whole blood high-shear viscosity)before and after treatment,as well as the adverse reactions,were compared between the 2 groups.Moreover,the clinical efficacy of the 2 groups was evaluated.RESULTS The efficacy of the intensive group was higher than that of the conventional group(x2=4.890,P=0.027).Compared with before treatment,the levels of TG,TC,LDL-C,plasma viscosity,whole blood low shear viscosity,and whole blood high shear viscosity in the intensive group and conventional group were reduced after treatment.In contrast,the levels of HDL-C,SDANN,SDNN,and pNN50 were increased(P＜0.05).After treatment,compared with the conventional group,the levels of TG,TC,LDL-C,plasma viscosity,whole blood low shear viscosity,and whole blood high shear viscosity in the intensive group were reduced.In contrast,the levels of HDL-C,SDANN,SDNN,and pNN50 were increased(P＜0.05).There was no difference in the incidence of adverse reactions between 2 groups(P＞0.05).CONCLUSION Rosuvastatin-intensive lipid-lowering therapy demonstrates significant clinical efficacy in coronary heart disease patients by regulating lipid profiles,modulating heart rate variability,and improving hemorheological parameters,with favorable safety outcomes.关键词
瑞舒伐他汀/强化降脂方案/冠心病/血脂/心率变异性Key words
rosuvastatin/intensive lipid-lowering regimen/coronary heart disease/plasma lipid/heart rate variability分类
药学引用本文复制引用
胡文奕,张思思,谢达奇..瑞舒伐他汀强化降脂方案对冠心病患者血脂及心率变异性的影响[J].中国临床药学杂志,2025,34(4):296-300,5.基金项目
宁波市公益性科技计划项目(编号2023S084) （编号2023S084）
